Oxford Biomedica PLC/ GB00BDFBVT43 /
2024-08-01 4:59:10 PM | Chg. -3.00 | Volume | Bid5:30:00 PM | Ask5:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
370.50GBX | -0.80% | 7,256 Turnover(GBP): 27,420.0550 |
-Bid Size: - | -Ask Size: - | 297.77 mill.GBP | - | - |
GlobeNewswire
03-06
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire
03-05
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire
01-23
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire
01-07
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire
01-03
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire
2023-12-04
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire
2023-11-09
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-09-20
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire
2023-09-20
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire
2022-03-23
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
GlobeNewswire
2022-03-17
Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Upda...
GlobeNewswire
2022-03-11
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solution...
GlobeNewswire
2022-03-10
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Cap...
GlobeNewswire
2022-01-31
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosido...
GlobeNewswire
2022-01-28
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ establ...